Publish in OALib Journal
APC: Only $99
of HPV tests into cervical cancer screening programs may be advantageous over
conventional cytology, especially in developing nations, where the largest
burden of cervical cancer is observed. Objectives: To conduct an evaluation of
commercially available molecular HPV tests in Brazilian women. Study design:
Two groups were recruited: group A was composed of 511 women referred to the
clinics because of a previous abnormal Pap test while group B consisted of 2464
subjects under routine screening. Cervical samples were collected using
SurePath liquid cytology (LBC) device, and split into aliquots which were
submitted to molecular testing by Hybrid Capture and cobas HPV. Colposcopy and
biopsies were made according to the standard guidelines, directed by
cytological diagnosis. Results: Prevalence of HSIL was 5.97% and 0.7% in Group A and B respectively.
High-Risk HPV DNA was found in about 9% of group B women, while in group A this
frequency was 24%. Having CIN3+ as the study end-point, the negative predictive
values for molecular methods were above 99.8%. All “in-situ” and
invasive cervical carcinomas were detected by both HPV nucleic acid assays.
Conclusion: Use of HPV DNA testing was feasible and highly sensitive in cancer
screening settings of Brazil.